Related by context. Frequent words. (Click for all words.) 83 Prodarsan ® 71 Cockayne Syndrome 71 Initiates Phase II 71 inflammatory autoimmune diseases 70 Meets Primary Endpoint 69 cutaneous T 69 VEGFR2 inhibitor 69 human lactoferrin 69 refractory chronic lymphocytic 69 Sapacitabine 69 Receives Orphan Drug Designation 69 Factor VIIa 68 Panzem R 68 ZFP Therapeutics 68 ZFP Therapeutic 68 GVAX R 68 liposomal formulation 68 Romidepsin 68 Drug Candidate 68 AEG# 68 Onalta 67 MKC# 67 gastrointestinal mucositis 67 Cetrorelix 67 Hepatitis C Virus HCV 67 PSMA ADC 67 CDAD Clostridium difficile 67 forodesine 67 Recombinant Human 67 Monoclonal Antibody 67 ThermoDox R 67 Pivotal Phase III 67 KNS # 67 preclinical efficacy 67 Presents Positive 67 ® bortezomib 67 TTR amyloidosis 66 Fast Track Status 66 Azedra 66 Belimumab 66 metastatic colorectal 66 DermaVir Patch 66 Mipomersen 66 Aerosurf 66 non alcoholic steatohepatitis 66 Phase IIb clinical trials 66 cardio renal 66 ALN TTR 66 MEK inhibitor 66 Epratuzumab 66 TELINTRA 66 Phase III Clinical Trial 66 ZFN TM 66 Rhucin R 66 endocrine diseases 66 FDA Accepts 66 C1 esterase inhibitor 66 multi kinase inhibitor 66 Vandetanib 65 Locteron ® 65 immunologic diseases 65 BioSilicon TM 65 2 methoxyestradiol 65 huC# DM4 65 R sorafenib tablets 65 Initiate Phase 65 topical non steroidal 65 non personalized allogeneic 65 factor VIIa 65 histone deacetylase HDAC inhibitor 65 Amgen discovers develops 65 therapeutic monoclonal antibodies 65 commercializing therapeutic 65 Pivotal Phase 65 includes investigational compounds 65 Kuvan R 65 Dapagliflozin 65 Nanobody 65 Commences Phase 65 interferon gamma 1b 65 Completes Enrollment 65 Eculizumab 65 developing Zerenex TM 65 rheumatoid arthritis psoriatic arthritis 65 CEQ# 65 Study Evaluating 65 ATL# [001] 65 elotuzumab 65 GSK# [002] 65 Patient Enrollment 65 commercializes therapeutic proteins 65 sodium Injection 65 Inhalation Solution 65 Genasense ® oblimersen 65 phenylalanine ammonia lyase 65 ALN TTR# 65 TLR9 agonist 65 Drug Shows Promise 65 Entereg R 65 REGN# 65 Currently RegeneRx